Acacia Pharma Group (ACPGF) Stock Price, News & Analysis

Company Overview

Acacia Pharma Group plc was a specialty pharmaceutical company focused on developing and commercializing medicines for acute-care settings, particularly treatments used in hospitals and other clinical environments.

Its principal commercial product was BARHEMSYS (amisulpride) injection, approved in the United States for the prevention and treatment of postoperative nausea and vomiting in adults. The company concentrated primarily on the U.S. market and was headquartered in Cambridge, United Kingdom.

Acacia Pharma was acquired by Eagle Pharmaceuticals in 2022 and became part of Eagle’s business. As a result, Acacia Pharma Group is primarily of historical interest as an independent publicly traded company.

Key Stats

• Today's Range: $0.99 to $0.99
• 50-Day Range: $0.99 to $0.99
• 52-Week Range: $0.76 to $4.00
• Volume: N/A
• Average Volume: 4,104 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals - Major
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ACPGF
• CIK: N/A
• Web: www.acaciapharma.com
• Phone: 44 1223 919760
• Fax: N/A
• Employees: 72
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A